Amphastar Pharmaceuticals Q3 EPS USD 0.87

AMPH•2026-11-05

Amphastar Pharmaceuticals reported Q3 EPS of USD 0.87 and adjusted EPS of USD 1.14, versus an estimate of USD 0.86. Revenue was USD 207.608 million, and net income was USD 37.763 million.

1. Quarterly results

Amphastar Pharmaceuticals reported Q3 adjusted EPS of USD 1.14, compared with the IBES estimate of USD 0.86. Revenue was USD 207.608 million versus an estimate of USD 197.9 million. Net income was USD 37.763 million, while adjusted net income was USD 49.265 million versus an estimate of USD 37.9 million.

Amphastar Pharmaceuticals Q3 EPS USD 0.87

1. Quarterly results

Related News

Trupanion Q3 revenue slightly beats estimates on subscription growth

Devon Energy tops profit estimates on higher output, crude prices

Pyxus International posts Q2 profit on Brazil facility sale

Castellum swings to Q3 2026 net loss of $453,904 year over year

Northern Oil & Gas Q3 2026 net loss narrows 13% year over year to $111.81 million